Cargando…

Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS

BACKGROUND: Triazole antifungals are widely used as broad-spectrum antifungal activity; however, there are many undetected and unreported adverse events (AEs). METHODS: Data from the Food and Drug Administration Adverse Event Reporting System (FAERS) from the first quarter (Q1) of 2004 to the third...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chai, Shuang, Zhan, Jing-Lun, Zhao, Li-Mei, Liu, Xiao-Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761248/ https://www.ncbi.nlm.nih.gov/pubmed/36545565 http://dx.doi.org/10.1177/20420986221143266

Ejemplares similares

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
por: Zhou, Xiang, et al.
Publicado: (2021)

Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS
por: Feng, Zhen, et al.
Publicado: (2022)

Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database
por: Wan, Qing, et al.
Publicado: (2022)

Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database
por: Shu, Yamin, et al.
Publicado: (2022)

GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS
por: Yang, Zheng, et al.
Publicado: (2022)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
por: Li, Meng, et al.
Publicado: (2022)

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
por: Liu, Wensheng, et al.
Publicado: (2023)

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
por: Chen, Chenxin, et al.
Publicado: (2021)

Electrolyte Disorders Associated with Piperacillin/Tazobactam: A Pharmacovigilance Study Using the FAERS Database
por: Seo, Heenam, et al.
Publicado: (2023)

Psychotropic drugs cross-reactivity with amphetamines in a FAERS sample: an international pharmacovigilance study
por: Giacovelli, L., et al.
Publicado: (2022)

Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
por: Teng, Chengwen, et al.
Publicado: (2019)

Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
por: Teng, Chengwen, et al.
Publicado: (2021)

Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)
por: Vestergaard Kvist, Annika, et al.
Publicado: (2021)

Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS
por: Tang, Shu, et al.
Publicado: (2022)

Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS
por: Wu, Bin, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
por: Yin, Yanchao, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
por: Yang, Yang, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
por: Guo, Menglin, et al.
Publicado: (2022)

Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study
por: Huang, Jing, et al.
Publicado: (2023)

Pharmacotherapy Management for COVID-19 and Cardiac Safety: A Data Mining Approach for Pharmacovigilance Evidence from the FDA Adverse Event Reporting System (FAERS)
por: Yuan, Jing, et al.
Publicado: (2021)

Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

Poly(ADP-ribose) polymerase inhibitor-associated myelodysplastic syndrome/acute myeloid leukemia: a pharmacovigilance analysis of the FAERS database
por: Ma, Z., et al.
Publicado: (2021)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
por: Cui, Zhiwei, et al.
Publicado: (2023)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Ma, Zhuo, et al.
Publicado: (2021)

Pharmacovigilance study of the association between dipeptidyl peptidase–4 inhibitors and angioedema using the FDA Adverse Event Reporting System (FAERS)
por: Ohyama, Katsuhiro, et al.
Publicado: (2022)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
por: Zhou, Chaozheng, et al.
Publicado: (2023)

Heparin-induced thrombocytopenia associated with low-molecular-weight heparin: clinical feature analysis of cases and pharmacovigilance assessment of the FAERS database
por: Liu, Leping, et al.
Publicado: (2023)

Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
por: Chiappini, Stefania, et al.
Publicado: (2023)

The potential antidepressant effect of antidiabetic agents: New insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase
por: Battini, Vera, et al.
Publicado: (2023)

Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022
por: Wang, Yanfeng, et al.
Publicado: (2023)

A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases
por: Chiappini, Stefania, et al.
Publicado: (2022)

Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data
por: Santi Laurini, Greta, et al.
Publicado: (2022)

Triazole derivatives with improved in vitro antifungal activity over azole drugs
por: Yu, Shichong, et al.
Publicado: (2014)

Pharmacovigilance: Safety matters…
por: Biswas, Pipasha
Publicado: (2008)

Advances in synthetic approach to and antifungal activity of triazoles
por: Shalini, Kumari, et al.
Publicado: (2011)

Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)
por: Zhao, Ying, et al.
Publicado: (2022)

Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS)
por: Chiappini, Stefania, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s72ec4ihqfmsp2urqgr8j0ovtg